摘要:
PROBLEM TO BE SOLVED: To develop a histamine release inhibitor comprising adenosine, adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP). SOLUTION: (1) This histamine release inhibitor comprises the adenosine. (2) The histamine release inhibitor comprises the adenosine monophosphate (AMP). (3) The histamine release inhibitor comprises the adenosine diphosphate (ADP). (4) The histamine release inhibitor comprises the adenosine triphosphate (ATP). (5) The histamine release inhibitor comprises the adenosine obtained from Phellinus linteus mycelia. COPYRIGHT: (C)2004,JPO&NCIPI
摘要:
PROBLEM TO BE SOLVED: To provide a hot-water extract comprising a substance having a physiological activity to humans, obtained from a fruit body of white to yellow Ganoderma lucidum, and cosmetics, health food and an anticancer drug each comprising the same. SOLUTION: Disclosed are, (1) a hot-water extract comprising a substance having physiological activity to humans, obtained from a fruit body of white to yellow Ganoderma lucidum, (2) a hot-water extract according to (1), wherein the substance having physiological activity to humans has a growth-promotion action on a normal human fibroblast (NB1RGB), (3) a hot-water extract according to (1), wherein the substance having physiological activity to humans has a tyrosinase inhibitory action, (4) a hot-water extract according to (1), wherein the substance having physiological activity to humans has an antioxidative action, (5) a hot-water extract according to (1), wherein the substance having physiological activity to humans has an antitumor effect, and (6) health food of low bitterness hardly containing ganoderic acid or the like and comprising the above hot-water extracts. COPYRIGHT: (C)2010,JPO&INPIT
摘要:
PROBLEM TO BE SOLVED: To obtain an adjuvant against a virus- or pathogenic bacterium-derived inactivated antigen. SOLUTION: (1) The adjuvant against a virus- or pathogenic bacterium-derived inactivated antigen comprises an extract of mushroom mycelium with hot water as a main component. (2) The secretory IgA antibody inducer comprises a virus- or pathogenic bacterium-derived inactivated antigen and the adjuvant against a virus- or pathogenic bacterium-derived inactivated antigen. (3) The method for inducing a viral or pathogenic bacterium-specific IgA antibody comprises administering a virus- or pathogenic bacterium-derived inactivated antigen and the adjuvant against the virus- or pathogenic bacterium-derived inactivated antigen. COPYRIGHT: (C)2009,JPO&INPIT
摘要:
PROBLEM TO BE SOLVED: To provide a mushroom bed cultivation method of ornamental Ganoderma lucidum which has appearance completely different from that of conventional Ganoderma lucidum and presents a white or yellow stag horn. SOLUTION: This mushroom bed cultivation method of ornamental white or yellow Ganoderma lucidum is performed in a housing and comprises inoculating hypha of Ganoderma lucidum to a mushroom bed followed by growing thick, storing the mushroom bed in a housing followed by holding, and keeping the housing in (A)-(C) conditions and raising carpophore of Ganoderma lucidum. (A) To cover the upper part of the housing with a semi-translucent material so as to bring a transmission rate to 65-85% until Ganoderma lucidum passes through bud cutting (sprouting) and infant Ganoderma lucidum starts to change color, after storing the mushroom bed in the housing. (B) To densely cover the upper surface of the housing with a shading material so as to increase airtightness and completely block light before the infant Ganoderma lucidum changes color to blackish brown after bud cutting. (C) To adjust a temperature in space of the housing to 25-35°C, and humidity to ≥90% and retain the condition. COPYRIGHT: (C)2009,JPO&INPIT
摘要:
PROBLEM TO BE SOLVED: To provide a cultivation method of decorative Ganoderma lucidum having completely different appearance from conventional Ganoderma lucidum and showing white or yellow deer horn. SOLUTION: This artificial cultivation method of the decorative white or yellow Ganoderma lucidum, to be performed in a housing comprises inoculating hypha of Ganoderma lucidum to cut shiitake log of broadleaf tree followed by growing thick, burying the cut shiitake log into soil in the housing to an extent allowing to see the cut surface, and maintaining the housing to grow carpophore of Ganoderma lucidum in (A)-(C) conditions as follows. (A) Until young Ganoderma lucidum starts to change color, passing from burying to sprouting, the upper part of the housing is covered with a semi-translucent object so as to bring a transmission rate to 65-85%. (B) Before the young Ganoderma lucidum changes to a blackish brown color after cutting buds, the upper surface of the housing is densely covered with a shade material so as to increase airtightness and completely block light. (C) A temperature in space of the housing is adjusted to 25-35°C and a relative humidity, to ≥90% and the condition is maintained. COPYRIGHT: (C)2008,JPO&INPIT
摘要:
PROBLEM TO BE SOLVED: To obtain a histamine release inhibitor. SOLUTION: This invention provides (1) a histamine release inhibitor containing N-hydroxy-N-methyl-adenosine and (2) the histamine release inhibitor containing the N-hydroxy-N-methyl-adenosine derived from the mycelia of Phellinus linteus. COPYRIGHT: (C)2005,JPO&NCIPI
摘要:
PROBLEM TO BE SOLVED: To provide a cyathane derivative (named as erinacineJ) and an antibacterial agent containing the derivative as an active component, especially an antibacterial agent effective against MRSA (methicillin resistant Staphylococcus aureus). SOLUTION: The invention provides (1) a cyathane derivative expressed by structural formula, (2) an antibacterial agent containing the cyathane derivative as an active component and (3) an antibacterial agent for MRSA containing the cyathane derivative as an active component. COPYRIGHT: (C)2005,JPO&NCIPI
摘要:
PROBLEM TO BE SOLVED: To obtain a histamine release inhibitor on the basis of knowledge that a substance derived from a mycelium of Phellinus linteus has inhibitory action on histamine release, and to provide a method for producing the same. SOLUTION: (1) The histamine release inhibitor comprises the substance derived from the mycelium of Phellinus linteus. (2) The histamine release inhibitor comprises an extract of Phellinus linteus with hot water. (3) The histamine release inhibitor comprises a methanol-soluble fraction in the extract of Phellinus linteus with hot water. (4) The histamine release inhibitor comprises a methanol-eluted fraction of the methanol-soluble fraction in the extract of Phellinus linteus with hot water adsorbed on an ion adsorbent. (5) The histamine release inhibitor comprises a component having 200-1,000 molecular weight in the methanol-eluted fraction. (6) The method for producing the histamine release inhibitor comprises making the histamine release inhibitor into dry powder and mixing the dry powder with another food powder. COPYRIGHT: (C)2004,JPO
摘要:
PROBLEM TO BE SOLVED: To provide a new prophylactic or therapeutic agent having effects on diseases based on cerebrovascular disorder and a health food for prevention or treatment. SOLUTION: (1) The prophylactic or therapeutic agent for diseases based on cerebrovascular disorder comprises a liquid culture solution (derived component) of mycelium of Phellinus Linteus as an active ingredient. (2) The cerebrovascular disorder is cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage or cerebral edema in the prophylactic or therapeutic agent described in (1). (3) The health food for preventing or treating diseases based on cerebrovascular disorder comprises a liquid culture solution (derived component) of a mycelium of Phellinus Linteus as an active ingredient. (4) The disease based on cerebrovascular disorder is cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage or cerebral edema, in the health food for preventing or treating diseases based on cerebrovascular disorder described in (3). COPYRIGHT: (C)2009,JPO&INPIT
摘要:
PROBLEM TO BE SOLVED: To obtain a histamine release inhibitor containing a nucleoside derived from RNA. SOLUTION: This invention provides (1) the histamine release inhibitor containing the nucleoside derived from RNA, (2) a histamine release inhibitor of the item (1) wherein the nucleoside derived from RNA is adenosine, (3) a histamine release inhibitor of the item (1) wherein the nucleoside derived from RNA is guanosine, (4) a histamine release inhibitor of the item (1) wherein the nucleoside derived from RNA is cytidine and (5) a histamine release inhibitor of the item (1) wherein the nucleoside derived from RNA is uridine. COPYRIGHT: (C)2005,JPO&NCIPI